在Pedunculoside及其Beta-CD聚合物包容复合物的体外稳定性和药理动力学研究
Liang Wu1,2, Danfeng Li1, Peijing Wang1
1School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Pharmaceutics
|May 25, 2024
概括
一种新型β-环氧烯聚合物复合物 (pedunculoside-βCDP) 通过改善血暴露和减少排泄,增强了潜在的心血管药物pedunculoside的生物可用性和药物动力学特征.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
- 自然产品 自然产品
背景情况:
- 来自伊莱克斯物种的三二烯沙波宁Pedunculoside在心血管疾病方面显示出有前途.
- 临床使用受到生物可用性差,快速排泄和肠道广泛代谢到轮酸的限制.
研究的目的:
- 准备一个水溶性纳入复杂的pedunculoside与β-cyclodextrin聚合物 (pedunculoside-βCDP).
- 为了比较pedunculoside和pedunculoside-βCDP的体外稳定性和体内药理动力学行为.
主要方法:
- 准备和表征丁化物-βCDP.
- 在模拟的胃和肠液以及特定的肠道细菌中进行体外稳定性研究.
- 开发和验证一种LC-MS/MS方法,用于在老鼠血中量化pedunculoside和rotundic酸.
- 向大鼠静脉注射佩登古赛德和佩登古赛德-βCDP,以评估药物动力学参数.
主要成果:
- 这两种化合物在模拟的胃和肠液中都表现出良好的稳定性.
- 观察到Bifidobacterium adolescentis和Bifidobacterium breve具有显著的新陈代谢.
- 佩登古化物-βCDP显著改善了佩登古化物的药物动力学特征,增加了血暴露,降低了排泄率.
- 在肠道中,pedunculoside的代谢被βCDP复合物降低.
结论:
- Pedunculoside-βCDP有效地增强了pedunculoside的药物动力学特性.
- 这种配方策略有可能推动pedunculoside在心血管治疗中的临床应用.
- 需要进一步研究pedunculoside-βCDP的代谢命运和药理动力学.
相关概念视频
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
299
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
299
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
198
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
198


